Savant Capital LLC Trims Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Savant Capital LLC trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 77.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,766 shares of the biopharmaceutical company’s stock after selling 12,825 shares during the period. Savant Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $1,228,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Atlantic Union Bankshares Corp purchased a new position in Alnylam Pharmaceuticals during the second quarter worth $30,000. SVB Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $27,000. Ameritas Advisory Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $42,000. AlphaQuest LLC purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $43,000. Finally, Steph & Co. acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $60,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ ALNY opened at $452.74 on Thursday. The stock has a market capitalization of $59.81 billion, a PE ratio of -183.30 and a beta of 0.30. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The firm has a fifty day moving average of $458.85 and a 200-day moving average of $381.24. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $1.51. The firm had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $943.37 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s revenue for the quarter was up 149.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.50) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Raymond James Financial began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price target on the stock. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday. Evercore ISI increased their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $482.17.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director directly owned 775 shares of the company’s stock, valued at $362,390. The trade was a 95.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Pushkal Garg sold 3,022 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company’s stock, valued at $9,129,377.08. The trade was a 13.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 66,696 shares of company stock worth $30,430,694. 1.20% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.